Upsher-Smith announces exclusive agreement with emerging pharmaceutical company

Upsher-Smith has announced an exclusive agreement with an emerging pharmaceutical company. | shutterstock

Upsher-Smith Laboratories Inc. recently announced it has entered into an exclusive agreement with an emerging pharmaceutical company for the marketing and distribution of a generic central nervous system (CNS) product.

IMS Health reported that recent sales in the United States of the product totaled more than $200 million for a 12-month period ending in June of this year. The new partnership is part of Upsher-Smith’s effort to increase its generic portfolio and its expansion into strategic partnerships in the pharmaceutical industry.

"Upsher-Smith has long been recognized within the pharmaceutical industry as a trusted name in the generics marketplace," Upsher-Smith President Rusty Field said. "This new agreement demonstrates the company's commitment to expanding its portfolio of high-quality, high-value generic products for patients."

Under the terms of the agreement, Upsher-Smith’s partner will have exclusivity to the development, manufacturing and supplying of the product while Upsher-Smith markets and distributes it in the U.S. under its own label. The financial terms of the deal have not yet been released.

Want to get notified whenever we write about Upsher-Smith Laboratories, Inc. ?
Next time we write about Upsher-Smith Laboratories, Inc., we'll email you a link to the story. You may edit your settings or unsubscribe at any time.
Organizations in this story

Upsher-Smith Laboratories, Inc. 6701 Evenstad Dr N Maple Grove, MN 55369-6026